Trials / Completed
CompletedNCT06046014
Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors
Determining the Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 15 Years – 39 Years
- Healthy volunteers
- Not accepted
Summary
Each year, about 89,500 adolescents and young adults (AYAs; 15-39 years old) are diagnosed with cancer and up to 60% experience body image (BI) distress. BI is largely developed in adolescence and young adulthood and has implications for self-identity and quality of life. Cancer itself and its associated treatments precipitate changes to appearance as well as body sensation and function, all of which can alter BI and lead to increased anxiety. An in-home BI-focused expressive writing (EW) program offers a promising outlet for addressing BI distress and anxiety in a way that eliminates constraints of clinical time and specialist availability. There are no recommended interventions to help AYA cancer survivors cope with BI distress. To address this knowledge gap, the objective of this this pilot randomized-controlled trial is to determine the feasibility of a four-week BI-focused EW intervention to decrease BI distress and anxiety among AYA cancer survivors with the hypothesis that this intervention will reduce BI distress and anxiety.
Detailed description
Protocol was updated to make the previous secondary outcome measures now exploratory
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | BI Focused writing | BI Focused writing program |
| OTHER | Control | Attention Control Writing |
Timeline
- Start date
- 2024-09-14
- Primary completion
- 2025-06-01
- Completion
- 2025-06-01
- First posted
- 2023-09-21
- Last updated
- 2025-09-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06046014. Inclusion in this directory is not an endorsement.